TriSalus Life Sciences (TLSI) Profit After Tax (2021 - 2026)

TriSalus Life Sciences has reported Profit After Tax for 6 years, with the latest figure at $1.5 million in Q1 2026.

• For the quarter ending Q1 2026, Profit After Tax rose 114.83% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2026 stood at -$27.3 million (changed 0.36% YoY), and the FY2025 full-year result was -$39.2 million, down 30.56% from the prior year.
• Profit After Tax for Q1 2026 stood at $1.5 million, up from -$9.8 million in the prior quarter.
• The five-year high for Profit After Tax was $1.5 million in Q1 2026, with the low at -$35.6 million in Q4 2023.
• Historically, Profit After Tax has averaged -$10.3 million across 5 years, with a median of -$8.7 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax plunged 2390.78% — and 2026, when it jumped 114.83%.
• TriSalus Life Sciences' Profit After Tax stood at -$22.5 million in 2022, then tumbled by 58.1% to -$35.6 million in 2023, then soared by 71.64% to -$10.1 million in 2024, then gained by 3.51% to -$9.8 million in 2025, then surged by 115.78% to $1.5 million in 2026.
• The last three Profit After Tax figures came in at $1.5 million (Q1 2026), -$9.8 million (Q4 2025), and -$10.8 million (Q3 2025), per Business Quant data.